Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy

Elodie Picarda, Kim C. Ohaegbulam, Xingxing Zang

Research output: Contribution to journalArticlepeer-review

328 Scopus citations


B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28 families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition of T-cell function. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Challenges remain to identify the receptor(s) of B7-H3 and thus better elucidate the role of the B7-H3 pathway in immune responses and tumor evasion. With a preferential expression on tumor cells, B7-H3 is an attractive target for cancer immunotherapy. Based on the clinical success of inhibitory immune checkpoint blockade (CTLA-4, PD-1, and PD-L1), mAbs against B7-H3 appear to be a promising therapeutic strategy worthy of development. An unconventional mAb against B7-H3 with antibody-dependent cell-mediated cytotoxicity is currently being evaluated in a phase I clinical trial and has shown encouraging preliminary results. Additional therapeutic approaches in targeting B7-H3, such as blocking mAbs, bispecific mAbs, chimeric antigen receptor T cells, small-molecule inhibitors, and combination therapies, should be evaluated, as these technologies have already shown positive results in various cancer settings. A better understanding of the B7-H3 pathway in humans will surely help to further optimize associated cancer immunotherapies.

Original languageEnglish (US)
Pages (from-to)3425-3431
Number of pages7
JournalClinical Cancer Research
Issue number14
StatePublished - Jul 15 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy'. Together they form a unique fingerprint.

Cite this